63 results about "Bone lesion" patented technology

Methods and systems for evaluating bone lesions include accessing a first dataset acquired from a patient with a first imaging modality and a second dataset acquired from the patient with a second imaging modality. A segmentation is performed on the first dataset to identify a subset of the first dataset corresponding to a skeletal structure of the patient and a patient skeletal metric representing a total bone volume of the patient is automatically calculated from the subset of the first dataset. The methods and systems further include detection of at least one lesion in the second dataset, classification of the at least one lesion as a bone or non-bone lesion, automatic calculation of a bone lesion metric based on the classification, and calculation of a lesion burden as a ratio of the bone lesion metric and the patient skeletal metric.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3 / FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed.

This invention relates to pyrimidine compounds of formula (I), formula (I′), and formula (I″):and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, R5, U, V, W, X, Y, Z, and n are defined herein. This invention also relates to compositions comprising these compounds and methods for using them. The compounds and compositions of this invention are useful to treat or prevent disorders associated with excessive bone loss, including, without limitation periodontal disease, non-malignant bone disorders (such as osteoporosis, Pagers-disease of bone, osteogenesis imperfecta, fibrous dysplasia, and primary hyperparathyroidism) estrogen deficiency, inflammatory bone loss, bone malignancy, arthritis, osteopetrosis, and certain cancer-related disorders (such as hypercalcemia of malignancy (HCM), osteolytic bone lesions of multiple myeloma and osteolytic bone metastases of breast cancer and other metastatic cancers).

The invention discloses autofluorescence bone repairing magnetic sustained-release microspheres and a preparation method thereof. The method comprises the steps of synthesizing nano Fe3O4 by a solvothermal method; uniformly dispersing nano Fe3O4 into a sodium alginate solution while combining with a traditional Chinese medicine-icariin with proliferation and differentiation effects on osteoblast; enabling the mixture to pass through a microcapsule forming device, and dropwise adding the mixture into a gel bath to form primary microspheres; soaking the primary microspheres in a chitosan solution to form a polyelectrolyte semipermeable membrane by use of the charge complementation feature of chitosan and sodium alginate; crosslinking the composite microspheres with genipin to obtain the autofluorescence bone repairing magnetic sustained-release microspheres. According to the autofluorescence bone repairing magnetic sustained-release microspheres and preparation method thereof disclosed by the invention, the requirements of an implanted bone repairing material on cytotoxicity are taken into full consideration, the chitosan and sodium alginate with excellent biocompatibility and degradability are selected as raw materials, and the microspheres with different particle sizes can be prepared by adjusting the voltage according to the needs of the bone lesion.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3 / FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

The present invention relates generally to the fields of treatment, prophylaxis and diagnosis. More particularly, the present invention identifies genes and gene products associated with bone morphogenesis and pathologies of the bone. Even more particularly, the present invention contemplates the regulation of expression of these genes or the activity of the gene products in the treatment, prophylaxis and diagnosis of bone pathologies. Cell-based therapies and manipulation of cells in in vitro culture also form part of the present invention.

The present invention relates to method for treating bone loss utilizing full length parathyroid hormone. The method dose not increase the risk of osteosarcoma or bone lesions.

The present invention relates to protein complexes or scaffold comprising cartilage oligomeric matrix protein (COMP) polypeptides bound to one or more growth factors, and methods of their use in promoting chondrogenesis and / or osteogenesis, and repair of cartilage and bone lesions.

The invention discloses a whole-body bone imaging bone segmentation method based on atlas registration. The method comprises the following steps: acquiring original whole-body bone imaging data collected by professional equipment; subjecting the original whole-body bone imaging data to preprocessing including pollution detection processing, pollution repair processing, standardization processing,registration processing and regularization processing; and according to a deformation segmentation template stored in the system, carrying out segmentation processing on the preprocessed whole-body bone development image to obtain a segmentation result of whole-body bone development. By means of the method, bone positioning can be conducted on an image obtained through single whole-body bone scanning examination, a basis is provided for bone lesion positioning, development quality is improved by automatically reducing a difference through bone development pollution detection and a pollution repair algorithm, and the development difference between different whole-body bone scans is solved; and rapid, accurate and intelligent positioning of the whole-body bone imaging skeleton is achieved.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3 / FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease reduce tumor burden in multiple myeloma and to block bone disease.

The invention relates to a bone connecting powder for treating traumatic injury, which is made from 5 to 15 parts of daphne giraldii nitsch, 5 to 10 parts of saffron, 5 to 15 parts of notoginseng, 5 to 15 parts of chuanxiong rhizome, 5 to 10 parts of frankincense, 5 to 10 parts of myrrh, 6 to 20 parts of dragons blood, 5 to 15 parts of sappan wood, 10 to 20 parts of angelica, 5 to 15 parts of pyrite, 5 to 10 parts of ground beetle, 3 to 8 parts of hippocampus, 5 to 10 parts of rhizoma drynariae, 3 to 8 parts of pilose deer horn, and 1 to 3 parts of musk in definite weight proportion The fifteen bulk drugs are jointly ground into fine powder, and processed to particles with a fineness of 120 meshes, and then mixed evenly and made into pulvis. The powder of the invention has the functions of promoting blood circulation to dispel blood stasis, reducing swelling and alleviating pain, and promoting reunion of the fractured bones, and has apparent analgesic effect on soft tissue fracture, comminuted fracture and old injuries, the early-stage and medium-stage osteonecrosis, compression fracture of lumbar vertebra, bone lesion, lumbar disc protrusion and the like in the bone injury treatment. The powder of the invention has the advantages of quick effect-taking, good curative effect, short treatment course, convenient use, being safe and reliable, and no side effect. The clinical effective rate of the powder for more than 1200 cases is 96 percent.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3 / FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

The invention relates to a method of treating mucopolysaccharidoses using enzyme replacement therapy with chemically modified lysosomal enzymes. More specifically the method relates to administering chemically modified lysosomal enzymes intraperitoneal injection. In addition, the invention relates to treating type VII mucopolysaccharidoses or mucopolysaccharidoses type VII related bone lesions with a chemical modified β-glucuronidase, wherein the modified β-glucuronidase may be administered 5 weeks after birth, and or may be administered intraperitoneally.

A composite medicine for preventing and treating the retrograde bone lesion, osteoporosis and osteoarthrodynia contains vegetable estrogen (30-50%) and aminoglocose (50-70%), and is prepared through extracting the vegetable estrogen from relative plant, preparing the aminoglocose hydrochloride (or sulfate) from the the shell of shrimp and crab or the chitin, and conventionally preparing said medicine. Its advantages are high curative effect and no toxic by-effect.

The invention discloses a spinal closed puncture guide, which can be specifically used for the puncture positioning of various parts of the spinal column such as intervertebral foramen, intervertebral disc, articular process and pedicle. It consists of an angle ruler, a ruler, a puncture needle guide, a positioning needle needle guide, an aiming ruler, a puncture needle and a positioning needle, the angle ruler is in the shape of a semi-circle, and the ruler slides vertically through the angle ruler , and can be locked by the angle ruler, the puncture needle guide is provided with two pieces, which are respectively slid on both ends of the angle ruler, and can be locked at any angle of the angle ruler, the two puncture needle guides no matter from the angle Any angle of the ruler guides the puncture needle to the same point on the center line of the angle ruler. The positioning needle needle guide is provided with two pieces, one is fixed on one end of the ruler, and the other is slid on the other side of the ruler. One end can be locked, and the positioning needle guide device guides the positioning needle to stick to the bone near the patient's lesion.

The invention relates to a filling stent material containing a three-layer structure and suitable for bone repairing and a preparation method of the filling stent material. The bottom end of a bone repairing stent has a multi-stage pore structure with high porosity, can slowly release bioactive factors and improve the inflammatory state of a bone lesion portion, has good biological activity and bone induction ability, and is beneficial to enhancing osteogenesis and bone remodelling; and an upper end is a bone cement matrix barrier layer with low porosity, and a middle layer is an adhesive layer. The composite stent provided by the invention utilizes a barrier effect of an upper layer and an osteogenesis promoting effect of a lower layer, and can effectively promote repairing and regeneration of bone tissues; and besides good adhesion and filling effects, the filling gel auxiliary material also has a bone growth promoting component, and has a synergistic effect with a skeleton.

The invention discloses a method of complementing a diseased bone to obtain a bone expected reference model. The method has the technical effects that the complementing form after bone lesion removalcan be quickly obtained, and the complementing form is basically close to natural bones; the method is not limited by complementation when the range of lesions is too large; and under the condition that clinical data and operator experience can not be considered, the trained model and the method can also be copied, and basic bone completion is completed. Therefore, the technical difficulty of theskeleton expected reference model is reduced, the manufacturing efficiency of the skeleton expected reference model is improved, and technical popularization and copying are facilitated.

Instrumentation sets and methods for preparing and implanting an osteochondral allograft to a bone lesion. Instrumentation sets include a pair of guide blocks, a recipient guide block and an allograft guide block, for preparing a cavity at the bone lesion matched by a similarly sized and shaped allograft. Guide blocks provide simple and direct techniques for preparing a matching cavity, formed at the bone lesion, to a bone implant, to be secured within the cavity. Methods include use of the instrumentation to restore bone surfaces for any number of sites using any allograft source. In some cases, the bone lesion is in a humeral head and the allograft source is a talus.

The invention discloses the application of multifunctional polymer vesicles to the preparation of a medicine for treating multiple myeloma. Protein which acts in the cells is loaded by an improved nanometer vesicle carrier, targeted delivery of the whole tumor cells is realized, the medicine is released rapidly in tumor cells, and the efficient and low-toxicity tumor treatment aim is fulfilled. The result indicates that HA-RCP-GrB has high anti-tumor efficiency and low toxic and / or side effects in multiple myeloma LP1 subcutaneous and in-situ tumor models, the lifetime of mice suffering from in-situ myeloma is obviously prolonged, and the states of bone lesions and damage to bone trabecula are greatly improved.

The invention discloses plaster for treating wind-cold-dampness arthralgia arthritis and bone lesion. Raw materials comprise a fried group and a fine group. The fried group comprises, by weight parts, 50-100 parts of dog bone, 50-100 parts of tortoise shell and 30-80 parts of mole cricket. The fine group comprises, by weight parts, 100-150 parts of chili powder and 60-120 parts of thuja sutchuenensis. The plaster is used for treating wind-cold-dampness arthralgia arthritis and bone lesion and has the advantages of being good in curative effect, taking effect quickly and being convenient to use.

The present invention pertains to an implant for treatment of a bone lesion site, the implant including a polymer porous film and a layer containing a biocompatible material, wherein the polymer porous film is a polymer porous membrane of a three-layer structure having a porous surface layer A, a porous surface layer B, and a macrovoid layer interposed between the surface layer A and the surface layer B; the average pore diameter of the pores in surface layer A is smaller than the average pore diameter of the pores in surface layer B; the macrovoid layer has a partition joined to the surface layers A and B and a plurality of macrovoids enclosed by the partition and the surface layers A and B; and the pores in the surface layers A and B communicate with the macrovoids.

Methods and systems for evaluating bone lesions include accessing a first dataset acquired from a patient with a first imaging modality and a second dataset acquired from the patient with a second imaging modality. A segmentation is performed on the first dataset to identify a subset of the first dataset corresponding to a skeletal structure of the patient and a patient skeletal metric representing a total bone volume of the patient is automatically calculated from the subset of the first dataset. The methods and systems further include detection of at least one lesion in the second dataset, classification of the at least one lesion as a bone or non-bone lesion, automatic calculation of a bone lesion metric based on the classification, and calculation of a lesion burden as a ratio of the bone lesion metric and the patient skeletal metric.

The invention, relating to the field of traditional Chinese medicine, discloses an externally dressed drug for treating fracture, solving the problems of bad curative effects, slow effect and the like in the prior art by combining modern pharmacological studies based on pathologic knowledge of fracture in traditional Chinese medicine. The drug comprises the following ingredients: 20-60 weight parts of eupolyphaga sinensis, 5-25 weight parts of dragon's blood, 15-40 weight parts of cassia twig, 15-25 weight parts of olibanum, 10-20 weight parts of rhizoma anemarrhenae, 5-15 weight parts of rhizoma corydalis, 10-20 weight parts of myrrh, 5-15 weight parts of cinnabar, 10-30 weight parts of achyranthes bidentata, 5-20 weight parts of pillis ophidiae, and 20-50 weight parts of Panax notoginseng powder. The drug of the invention is used for fracture and bone lesions. After fracture patients use the drug, the wound heals quickly without recurrence, the swelling is reduced quickly, and the pain is alleviated. After the fractures are healed, there is no side effect, and limbs can move normally.

Pharmaceutical compositions for treating bone lesions in multiple myeloma or pharmaceutical compositions for treating multiple myeloma which contain as an active ingredient a compound having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma, more particularly, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3 / FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to reduce tumor burden in multiple myeloma and to block bone disease.

The present invention refers to an osteochondral local prosthetic insert for partial humeral joint reconstitution by reconstitution of the bone anatomical sphericity to treat bone lesions, in particular Hill-Sachs lesions. The local osteochondral prosthetic insert is a rigid monolithic body having a truncated-cone shape, the proximal diameter greater than the distal diameter, the proximal end of convex shape and rounded at the corners, and a tapered distal end. The lateral surface of the insert shows in the middle-distal part a non-return shaping that allows the maintenance of the position defined in the surgical operation. The proximal end is convex in order to better adapt to the local bone sphericity and has recesses for the manipulation and positioning through dedicated tools.

The invention discloses a self-fluorescent bone repair magnetic slow-release microsphere and a preparation method thereof. The nano-Fe3O4 is synthesized by a solvothermal method, and the nano-Fe3O4 is uniformly dispersed in a sodium alginate solution, and the composite has the functions of promoting proliferation and promoting osteoblasts. Differentiation of traditional Chinese medicine - icariin; the mixture is passed through a microcapsule forming device and dropped into a gel bath to form primary microspheres; then the primary microspheres are immersed in chitosan solution, and chitosan and alginic acid are used to The charge complementary properties of sodium form a polyelectrolyte semipermeable membrane, and the composite microspheres are cross-linked with genipin to prepare autofluorescent magnetic sustained-release microspheres for bone repair. The present invention fully considers the requirement of cytotoxicity as an implantable bone repair material, selects chitosan and sodium alginate with excellent biocompatibility and degradability as raw materials, and can be adjusted according to the needs of bone lesions. Different voltages are used to prepare microspheres with different particle sizes.